KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Accumulated Expenses (2016 - 2022)

Historic Accumulated Expenses for Gilead Sciences (GILD) over the last 14 years, with Q3 2022 value amounting to $3.9 billion.

  • Gilead Sciences' Accumulated Expenses rose 222.16% to $3.9 billion in Q3 2022 from the same period last year, while for Sep 2022 it was $3.9 billion, marking a year-over-year increase of 222.16%. This contributed to the annual value of $6.1 billion for FY2021, which is 4172.05% up from last year.
  • Per Gilead Sciences' latest filing, its Accumulated Expenses stood at $3.9 billion for Q3 2022, which was up 222.16% from $4.1 billion recorded in Q2 2022.
  • Gilead Sciences' Accumulated Expenses' 5-year high stood at $6.1 billion during Q4 2021, with a 5-year trough of $3.5 billion in Q1 2020.
  • Moreover, its 5-year median value for Accumulated Expenses was $3.9 billion (2018), whereas its average is $4.1 billion.
  • Per our database at Business Quant, Gilead Sciences' Accumulated Expenses crashed by 2346.29% in 2019 and then surged by 4172.05% in 2021.
  • Over the past 5 years, Gilead Sciences' Accumulated Expenses (Quarter) stood at $3.9 billion in 2018, then decreased by 11.58% to $3.5 billion in 2019, then grew by 24.85% to $4.3 billion in 2020, then skyrocketed by 41.72% to $6.1 billion in 2021, then tumbled by 37.1% to $3.9 billion in 2022.
  • Its last three reported values are $3.9 billion in Q3 2022, $4.1 billion for Q2 2022, and $3.5 billion during Q1 2022.